Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: Impact on the practice

AIM: This multicenter study describes the effectiveness of eribulin in current practice. PATIENTS & METHODS: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled. RESULTS: The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable. CONCLUSION: Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic site

The new CGEM Inner Tracker and the new TIGER ASIC for the BES III Experiment

A new detector exploiting the technology of Gas Electron Multipliers is under construction to replace the innermost drift chamber of BESIII experiment, since its efficiency is compromised owing the high luminosity of Beijing Electron Positron Collider. The new inner tracker with a cylindrical shape will deploy several new features. The analogue readout and two complementary algorithms to reconstruct the position will allow achieving a spatial resolution of 130 µm in a 1 T magnetic field. For this purpose, TIGER, a new custom 64-channel ASIC, providing time and charge measurements, has been developed. Here, a summary of the most recent results on detector and electronics prototypes is given